Flexion (FLXN) Could Trade to $34 Following Data - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Flexion Therapeutics (FLXN) Fair Value Target Raised to $33 at Janney Capital
February 17, 2016 7:30 AM ESTJanney Capital analyst Ken Trbovich raised his fair value estimates on Buy-rated Flexion Therapeutics (NASDAQ: FLXN) to $33.00 (from $27.00) after the company reported its Phase 3 study of Zilretta achieved its primary endpoint with highly significant results.
:We see this as a major... More
Flexion Therapeutics (FLXN) Announces Zilretta Phase 3 Met Primary Endpoint in Knee Osteoarthritis
February 16, 2016 4:02 PM ESTFlexion Therapeutics, Inc. (Nasdaq: FLXN) reported that the Phase 3 clinical trial for its lead drug candidate Zilretta (also known as FX006) met its primary endpoint at week 12, demonstrating highly significant (p... More
